BIOLASCO TAIWAN CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.4 TWD | +0.55% |
|
+2.68% | +9.64% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2022 | 236M 7.28M 570M | Sales 2023 | 265M 8.17M 639M | Capitalization | 850M 26.25M 2.05B |
|---|---|---|---|---|---|
| Net income 2022 | 42M 1.3M 101M | Net income 2023 | 49M 1.51M 118M | EV / Sales 2022 | 2.56 x |
| Net cash position 2022 | 161M 4.98M 389M | Net cash position 2023 | 143M 4.43M 346M | EV / Sales 2023 | 2.67 x |
| P/E ratio 2022 |
18.1
x | P/E ratio 2023 |
17.1
x | Employees | 87 |
| Yield 2022 |
5.03% | Yield 2023 |
4.97% | Free-Float | 54.31% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.55% | ||
| 1 week | +2.68% | ||
| Current month | +0.55% | ||
| 1 month | +4.00% | ||
| 3 months | -5.70% | ||
| 6 months | +13.40% | ||
| Current year | +9.64% |
1 week
34.75
36.50
1 month
33.5536.50
Current year
32.7039.50
1 year
30.4039.50
3 years
28.6039.50
5 years
25.2560.00
10 years
25.2571.09
| Managers | Title | Age | Since |
|---|---|---|---|
Chen Chung Chen
CEO | Chief Executive Officer | - | 08/04/01 |
Yue Ching Yu
DFI | Director of Finance/CFO | - | 30/06/14 |
Lei Yao Chang
IRC | Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chen Chung Chen
CEO | Chief Executive Officer | - | 08/04/01 |
Li Chu Wu
BRD | Director/Board Member | - | 18/06/14 |
Chun Wei Chen
BRD | Director/Board Member | - | 21/06/17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/06/24 | 36.4 | +0.55% | 19,061 |
| 31/05/24 | 36.2 | +1.26% | 16,001 |
| 30/05/24 | 35.75 | 0.00% | 20,001 |
| 29/05/24 | 35.75 | +0.99% | 13,000 |
| 28/05/24 | 35.4 | -0.14% | 9,030 |
End-of-day quote Taipei Exchange, June 02, 2024
More quotes
BioLASCO Taiwan Co., Ltd. is a Taiwan-based company mainly engaged in the production of Specific Pathogen Free (SPF) laboratory animals and the high-value special-mode experimental animals, as well as the introduction and production of highly-applicable disease-mode animals. The company also provides equipment related to feeding, supplies and testing platform, life science research and pharmaceutical development services.
| 1st Jan change | Capi. | |
|---|---|---|
| +9.64% | 28.83M | |
| +48.64% | 56.65B | |
| -6.44% | 39.44B | |
| +38.14% | 39.03B | |
| +14.28% | 26.75B | |
| -11.17% | 26.86B | |
| -21.40% | 19.03B | |
| +25.64% | 12.26B | |
| +0.96% | 12.28B | |
| +27.04% | 12.04B |
- Stock Market
- Equities
- 6662 Stock